SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) Announces a Continued Benefit on Walking Test Through 62 Weeks in Phase IIb Open-Label Extension Study of Eteplirsen in Duchenne Muscular Dystrophy